Diamond-Blackfan anemia (DBA) is a congenital erythroid hypoplasia caused by a functional haploinsufficiency of genes encoding for ribosomal proteins.
validated the therapeutic effect of L-leucine using our recently generated mouse model for RPS19-deficient DBA. Administration of L-leucine significantly improved the anemia in Rps19-deficient mice (19 % improvement in hemoglobin concentration; 18% increase in the number of erythrocytes), increased the bone marrow cellularity and alleviated stress hematopoiesis. Furthermore, the therapeutic response to L-leucine appeared specific for Rps19-deficient hematopoiesis and was associated with downregulation of p53 activity. Our study supports the rationale for clinical trials of L-leucine as a therapeutic agent for DBA.
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INTRODUCTION
Diamond-Blackfan anemia (DBA) is a congenital erythroid hypoplasia characterized by macrocytic anemia with selective absence of erythroid precursors, physical abnormalities and cancer predisposition 1, 2, 3, 4 . Mutations in genes encoding for ribosomal proteins (RP) have been identified in approximately half of the DBA patients 5, 6, 7, 8, 9, 10, 11 . RPS19 is the most common DBA gene (25 % of the patients), the majority of the mutations resulting in RPS19 haploinsufficiency 12, 13 .
Corticosteroids and transfusion form the main therapeutic regimen in DBA . Leucine is an essential amino acid that plays an important role in the regulation of protein synthesis, and this response seems to involve the mammalian target of rapamycin (mTOR) pathway 16 . Furthermore, on a systemic level dietary leucine affects multiple metabolic and signaling pathways 17 . In the current study we have investigated the therapeutic potential of L-leucine in DBA using our recently generated mouse model for RPS19-deficient DBA 18 . L-leucine treatment significantly improves the number of erythrocytes and hemoglobin concentration in Rps19-deficient mice, and is associated with reduced p53 activity in hematopoietic progenitors. 
Blood and bone marrow cellularity
Peripheral blood was collected from the tail vein in Microvette tubes (Sarstedt) and analyzed using Sysmex XE-5000. Bone marrow cells were isolated by crushing both femurs and tibiae in PBS containing 2 % fetal calf serum (GIBCO), stained with Türk's solution (Merck) and counted in a Bürker chamber. 
Flow cytometry

Quantitative real-time PCR
Total RNA was isolated from FACS-sorted cells using RNAeasy micro kit (Qiagen) and cDNA transcribed with SuperScript III reverse trancriptase (Invitrogen). Real-time PCR reactions were performed using pre-designed assays (Applied Biosystems; Supplemental according to manufacturer's instructions (Invitrogen, 11761-500).
Statistical analyses
Student's t test was used to determine statistical significance, and two-tailed P values are shown.
RESULTS AND DISCUSSION
To study the therapeutic potential of L-leucine we took advantage of our recently generated mouse model for RPS19-deficient DBA 18 . This model contains an Administration of doxycycline to transgenic Rps19 knockdown mice results in a rapid reduction in bone marrow cellularity, and following this initial shock Rps19-deficient mice are partly able to compensate for the erythroid defect 18 . Monitoring the cellularity in blood and bone marrow during the first weeks after induction of the phenotype provides an excellent approach to test novel therapeutic agents enhancing Rps19-deficient hematopoiesis.
We chose to administer 1.5 % (w/v) L-leucine in the drinking water, a regimen that doubles the concentration of leucine in serum 17 , and simultaneously fed the mice with doxycycline-containing food pellets in order to induce Rps19 deficiency ( Figure 1A ). L-leucine administration had no significant effect on weight gain, and we observed no reduction in Rps19 knockdown efficiency ( Figure 1B , Supplemental figure 2). After two weeks of doxycycline administration Rps19-deficient mice showed a reduction in erythrocyte numbers and the hemoglobin concentration, and both parameters were significantly improved upon L-leucine treatment ( Figure 1C ). Reticulocytes were slightly increased but not statistically
significant. The effect on white blood cells appeared modest, while platelet count was reduced in both Rps19-deficient and control mice (Supplemental figure 3) .
Additionally, L-leucine had no effect on erythroid recovery in wild-type mice after sublethal irradiation or phenylhydrazine-induced hemolytic anemia (Supplemental Figure 4) .
The hypocellular bone marrow in Rps19-deficient mice was significantly improved upon L-leucine treatment ( Figure 1D ). Simultaneously, L-leucine treatment decreased the frequencies of hematopoietic stem and progenitor compartments ( Figure 1E ), as assessed by flow cytometry (Supplemental figure   5 ) 18, 19, 20 . Strikingly, the frequencies of all erythroblasts in Rps19-deficient mice were significantly reduced upon L-leucine treatment ( Figure 1F , and we have shown that the deletion of Trp53 rescues Rps19-deficient hematopoiesis 18 . L-leucine administration led to dampened expression of previously identified p53 transcriptional targets in Rps19-deficient Figure 2B ) 18 , demonstrating the reduced activity of p53 upon L-leucine treatment.
In conclusion, we demonstrate that the administration of L-leucine improves the anemia in a mouse model for RPS19-deficient DBA, and the therapeutic effect is associated with reduced p53 activity in hematopoietic progenitors. Our study thus supports the role of L-leucine as a therapeutic agent in the treatment of DBA. For personal use only. on October 4, 2017. by guest www.bloodjournal.org From
